• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Abbott wins CE Mark for next-gen Xience Sierra drug-eluting stent

October 30, 2017 By Brad Perriello

AbbottAbbott (NYSE:ABT) said today that it won CE Mark approval in the European Union for its next-generation drug-eluting stent, the Xience Sierra.

The everolimus-eluting coronary stent is designed to allow cardiologists to treat the complex lesions that make up roughly 70% of cases, the Chicago-area healthcare giant said. It offers a thinner profile, increased flexibility, longer lengths and smaller diameters than previous stents.

“Doctors tell us they need better tools to treat increasingly challenging cases, which involve multiple, or totally blocked arteries and complications such as diabetes,” vascular SVP Chuck Brynelsen said in prepared remarks. “We designed Xience Sierra with the goal of helping more people with coronary artery disease regain their health and return to their daily lives as quickly as possible.”

“Xience Sierra can help cardiologists be even more precise when implanting the stent, which is important for efficacy and safety,” added vascular chief medical officer Dr. Charles Simonton. “Its design, range of sizes and increased flexibility mean doctors don’t have to use as much force when they implant a Xience Sierra stent compared to other stents.”

Abbott said it’s also applied for U.S. approval from the FDA for Xience Sierra.

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Regulatory/Compliance, Stents Tagged With: abbott

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS